Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Advances in Hemophilia Treatment: Perspectives From Your Colleagues
The Promise and Future of Gene Therapy
Choose a format
Take 1 Minute Challenge
1 Minute Challenge Completed
Details
Presenters
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
Name of Individual
Role in Activity
Name of Commercial Interest(s)
Nature of Relationship(s)
Mechanism(s) implemented to resolve conflict of interest
Ashley Smeaton, MHA
TFF Staff
No relevant financial disclosures
N/A
N/A
Jenny McDaniel, MD
Planning Committee Member, Faculty
1. Sanofi
1. Non-CE Consulting (Advisory Board)
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted planning committee
Content was reviewed by a non-conflicted content reviewer to ensure that it is not commercially biased, is fair and balanced, and is based on scientific evidence and/or clinical reasoning
Melissa Glasner, MS
Planning Committee Member
No relevant financial disclosures
N/A
N/A
Heather Tarbox, MPH
TFF Staff
No relevant financial disclosures
N/A
N/A
Patrick Harty, PhD
TFF Content Reviewer
No relevant financial disclosures
N/A
N/A
Stephanie Ambrose, DO
Planning Committee Member, Faculty
1. BioMarin, CSL Behring, HEMA Biologics, Sanofi
1. Non-CE Consulting
All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted planning committee
Content was reviewed by a non-conflicted content reviewer to ensure that it is not commercially biased, is fair and balanced, and is based on scientific evidence and/or clinical reasoning
Disclosure of Unlabeled Use:
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Target Audience
This educational activity is intended for US-based hematology, pediatric, and adult primary care providers (physicians, PAs, and NPs)
Learning Objectives
Upon completion of this activity, learners should be able to:
- Assess how novel and emerging treatments may address the unmet needs of patients with hemophilia
- Compare the clinical profiles of novel and emerging therapies for hemophilia
- Outline strategies for preparing hemophilia care teams and patients for new and emerging therapies in hemophilia
Accreditation and Credit Designation Statements
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.Physician Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.All other health care professionals completing this course will be issued a statement of participation.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
COPYRIGHT INFORMATION
Copyright © 2025 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:- The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission
PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
Additional information regarding The France Foundation’s Privacy Policy can be viewed at http://www.francefoundation.com/privacy.
CONTACT INFORMATIONIf you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Provider(s)/Educational Partner(s)
This activity is provided by The France Foundation.
Commercial Support
This activity is supported by an independent medical educational grant from Sanofi.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
